Impressive results have been achieved by adoptively transferring T-cells expressing CD19-specific CARs with binding domains from murine mAbs to treat B-cell malignancies. T-cell mediated immune ...

By drastically enhancing the effectiveness of CD19 CAR T-cell therapies against lymphoma cells with low or no CD19 antigen expression, Aleta is set to increase B-cell cancer cure rates significantly.

Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

Sana revolutionizes treatments for diabetes, cancer, and autoimmune diseases. SANA has high cash burn and dilution risks. See ...

FDA grants fast track designation to azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large ...